Maintenance therapy for advanced lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a pill form of chemotherapy (oral paclitaxel) combined with an immunotherapy drug to keep advanced lung cancer from growing after initial treatment. It may help patients whose cancer was controlled with first-line therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have advanced lung cancer (either squamous non-small cell or small cell) that has not spread beyond the chest and is not curable with surgery or radiation.
- You must have completed four cycles of standard first-line treatment (immunotherapy plus chemotherapy) and your cancer has not progressed.
- You must be in generally good health, able to take care of yourself (ECOG performance status 0 or 1).
- Your last dose of first-line treatment must have been within 28 days of starting this trial.
- You must have adequate organ function and no serious immune-related side effects from previous immunotherapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two drugs for people with extensive-stage small cell lung cancer that has progressed after initial treatment. The goal is to see if this combination can help control the cancer.
This trial tests a combination of an immunotherapy drug (sintilimab) with chemotherapy and an anti-angiogenesis drug (rh-endostatin) for people with advanced or recurrent squamous non-small cell lung cancer. The goal is to see if this combination can shrink tumors and improve outcomes.
This trial tests a new way of giving radiation (in high and low doses) together with chemotherapy and immunotherapy to treat advanced non-small cell lung cancer. The goal is to see if this combination can shrink tumors and help patients live longer.
This study tests a combination of two medications given after initial chemotherapy to keep advanced squamous lung cancer from growing. It might help patients whose cancer has not spread too much and who are generally in good health.
This trial tests a new drug (SCTB41) combined with chemotherapy for people with advanced squamous non-small cell lung cancer who have not had any prior treatment. It aims to see if this combination works better than standard therapy.
This trial tests a new treatment that combines a drug called SYS6010 with an immunotherapy (Enlonstobart) compared to the usual immunotherapy plus chemo for advanced lung cancer. The goal is to see if this combo works better and helps people with PD-L1 positive lung cancer live longer and feel better.
Hear when a new Extensive-stage Small Cell Lung Cancer (ES-SCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.